Phase II clinical trial of intratumoral application of TG1042 (Adenovirus-interferon-γ) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas

Molecular Therapy

Volumn 18, Issue 6, 2010, Pages 1244-1247

  Dummer, Reinhard ^a   Eichmüller, Stefan ^b   Gellrich, Sylke ^c   Assaf, Chalid ^c,d   Dreno, Brigitte ^e   Schiller, Meinhard ^f   Dereure, Olivier ^g   Baudard, Marion ^h   Bagot, Martine ⁱ   Khammari, Amir ^e   Bleuzen, Pascal ^j   Bataille, Vincent ^j   Derbij, Anna ^j   Wiedemann, Nicole ^b   Waterboer, Tim ^b   Lusky, Monika ^j   Acres, Bruce ^j   Urosevic Maiwald, Mirjana ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HELIOS KLINIKUM KREFELD   (Germany)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g HÔPITAL SAINT ELOI   (France)

^h LAPEYRONIE HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j TRANSGENE S A   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; TG 1042; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CUTANEOUS B CELL LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE ESCALATION; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; INDUCED HYPOTHERMIA; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; ADENOVIRIDAE; GENETICS; INTRALESIONAL DRUG ADMINISTRATION; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; SKIN NEOPLASMS;

ADENOVIRIDAE;

ADENOVIRIDAE; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON-GAMMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; SKIN NEOPLASMS;

EID: 77953128821     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.52     Document Type: Article

References (16)

1. Kim, EJ, Hess, S, Richardson, SK, Newton, S, Showe, LC, Benoit, BM et al. (2005). Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 115: 798-812.
2. Willemze, R, Jaffe, ES, Burg, G, Cerroni, L, Berti, E, Swerdlow, SH et al. (2005). WHO-EORTC classifcation for cutaneous lymphomas. Blood 105: 3768-3785.
3. Rajan, GP, Seifert, B, Prümmer, O, Joller-Jemelka, HI, Burg, G and Dummer, R (1996). Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch Dermatol Res 288: 543-548.
4. Dummer, R and Dreyling, M; ESMO Guidelines Working Group (2008). Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 (suppl. 2): ii72-ii76.
5. Olsen, EA (2003). Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 16: 311-321.
6. Kaplan, EH, Rosen, ST, Norris, DB, Roenigk, HH Jr, Saks, SR and Bunn, PA Jr (1990). Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82: 208-212.
7. Jimbow, K, Yamana, K, Ishida, O, Kawamura, M, Ito, Y and Maeda, K (1987). [Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration]. Gan To Kagaku Ryoho 14: 152-158.
8. Heinzerling, L, Künzi, V, Oberholzer, PA, Kündig, T, Naim, H and Dummer, R (2005). Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106: 2287-2294.
9. Dummer, R, Hassel, JC, Fellenberg, F, Eichmüller, S, Maier, T, Slos, P et al. (2004). Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104: 1631-1638.
10. Urosevic, M, Fujii, K, Calmels, B, Laine, E, Kobert, N, Acres, B et al. (2007). Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J Clin Invest 117: 2834-2846.
11. Lusky, M (2005). Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 16: 281-291.
12. Senff, NJ, Noordijk, EM, Kim, YH, Bagot, M, Berti, E, Cerroni, L et al.; European Organization for Research and Treatment of Cancer; International Society for Cutaneous Lymphoma. (2008). European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112: 1600-1609.
13. Eichmuller, S, Usener, D, Dummer, R, Stein, A, Thiel, D and Schadendorf, D (2001). Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 98: 629-634.
14. Hartmann, TB, Thiel, D, Dummer, R, Schadendorf, D and Eichmüller, S (2004). SEREX identifcation of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol 150: 252-258.
15. Olsen, E, Vonderheid, E, Pimpinelli, N, Willemze, R, Kim, Y, Knobler, R et al.; ISCL/EORTC. (2007). Revisions to the staging and classifcation of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 1713-1722. (Pubitemid 47443880)
16. Kim, YH, Willemze, R, Pimpinelli, N, Whittaker, S, Olsen, EA, Ranki, A et al.; ISCL and the EORTC. (2007). TNM classifcation system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110: 479-484 (Pubitemid 47105384)